



# Cognitive symptoms in patients with Parkinson disease

Roberta Biundo, PhD

Chief Neuropsychologist at the Parkinson and movement disorders Unit, "I.R.C.S.S. Fondazione San Camillo", Venice, Italy

### **Outlines**

 Heterogeneity of cognitive profile in Parkinson's disease (PD): mix of different neuropsychological, neurochemical, clinical and neurosubstrates profiles.


 Screening of cognitive deficits for Parkinson MCI and dementia detection: structural interview, cognitive scales and neuropsychological assessments.

## Introduction

# PD as a Neuropsychiatric Disorder

- DSM-5 encapsulated
  - Depression, psychosis, cognitive impairment, impulse control disorders, anxiety, apathy, disorders of sleep and wakefulness
- Neural substrate relevant to neuropsychiatry
  - Brain <u>regions</u> (basal ganglia, prefrontal cortex), <u>neurotransmitters</u> (dopamine, norepinephrine, serotonin, acetylcholine and glutamate), <u>neural</u> <u>pathways</u> (cortico-striatal-thalamic circuitry)
- Inter- and intra-individual variability allows study- cognitive fluctuation

# Non-Motor Symptoms in PD Increasingly Recognized as Important



**FIG. 1.** Number of articles published devoted to Parkinson's disease, 1986–2010. *Cognition* = Parkinson\* and (dementia or cognitive impairment); *Depression* = Parkinson\* and depression; *Psychosis* = Parkinson\* and (psychosis or hallucination); *Anxiety* = Parkinson\* and anxiety; ICD's = Parkinson\* and (impulse control disorder or dopamine dysregulation syndrome); *Sleep and wakefulness* = Parkinson\* and (insomnia or sleepiness or fatigue or REM); *Apathy* = Parkinson\* and apathy.

## What Concerns Patients, Caregivers and Providers

#### Table 3 Final prioritised and ranked uncertainties for the management of Parkinson's disease

#### Overarching research aspiration: an effective cure for Parkinson's disease

- 1 What treatments are helpful for reducing balance problems and falls in people with Parkinson's?
- 2 What approaches are helpful for reducing stress and anxiety in people with Parkinson's?
- 3 What treatments are helpful for reducing dyskinesias (involuntary movements, which are a side effect of some medications) in people with Parkinson's?
- 4 Is it possible to identify different types of Parkinson's, eg, tremor dominant? And can we develop treatments to address these different types?
- 5 What best treats dementia in people with Parkinson's?
- 6 What best treats mild cognitive problems such as memory loss, lack of concentration, indecision and slowed thinking in people with Parkinson's?
- 7 What is the best method of monitoring a person with Parkinson's response to treatments?
- 8 What is helpful for improving the quality of sleep in people with Parkinson's?
- 9 What helps improve the dexterity (fine motor skills or coordination of small muscle movements) of people with Parkinson's so they can do up buttons, use computers, phones, remote controls etc?
- What treatments are helpful in reducing urinary problems (urgency, irritable bladder, incontinence) in people with Parkinson's?

## Limited Therapeutic Options Currently

## Therapeutic Prospects for Parkinson Disease

C. Warren Olanow, MD, FRCPC<sup>1</sup> and Anthony H. V. Schapira, MD, FRCP<sup>2</sup>

Dopaminergic therapies such as levodopa have provided benefit for millions of patients with Parkinson's disease (PD) and revolutionized the treatment of this disorder. However patients continue to experience disability despite the best of modern treatment. Dopaminergic and surgical therapies are associated with potentially serious side effects. Non-motor and non-dopaminergic features such as freezing, falling, and dementia are not adequately controlled with available medications and represent the major source of disability for advanced patients. And, the disease continues to relentlessly progress. Major therapeutic unmet needs include a dopaminergic therapy that is not associated with serious side effects, a therapy that addresses the non-motor and non-dopaminergic features of the disease, and a disease-modifying therapy that slows or stops disease progression. This review will consider current attempts to address these issues and the obstacles that must be overcome in order to develop more effective therapies for PD.

ANN NEUROL 2013;74:337-347


# Cognitive impairment

# Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease

Angie A Kehagia, Roger A Barker, Trevor W Robbins

	Type of deficit	Function
Wisconsin card sorting test Tower of London test	Executive	Attention Working memory Planning Concept formation Rule use Cognitive inhibition Use of feedback
Task switching	Executive	Cognitive flexibility Response inhibition Attention Resistance to distractibility or set maintenance
Stroop performance	Executive	Attention Response inhibition
Attentional set-shifting	Executive	Attention Higher-order flexibility (stimulus dimensions) Use of feedback Resistance to distractibility/set maintenance
Reversal learning	Learning	Use of feedback Lower-order flexibility (stimulus exemplars)
Weather prediction	Learning	Use of feedback Attention Working memory Rule formation Abstract reasoning
Gambling or decision making	Impulse control	Use of feedback Response inhibition
Digit span	Memory	Working memory (numbers)
Spatial working memory	Memory	Working memory (spatial representations)
Stop signal task	Motor inhibition	Response inhibition
Delayed responding	Motor inhibition	Attention Resistance to distractibility
	Visuospatial	Motor imagery

## Prefrontal Cortex-striatum networks



# Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease

Angie A Kehagia, Roger A Barker, Trevor W Robbins

#### Panel 1: Effects of dopamine restoration

#### Cognitive benefit or amelioration of deficit

- Wisconsin card sorting test
- Tower of London test
- Task switching—concrete rules
- Digit span
- Spatial working memory

#### Cognitive deterioration from dopaminergic overdose


- Concurrent learning
- Probabilistic reversal learning
- Weather prediction classification
- Gambling and decision making
- Delayed responding with distraction
- Visual hallucinations

#### No effect

- Attentional set-shifting (extra-dimensional shifting)
- Task switching—abstract rules
- Pattern and spatial recognition memory
- Associative learning
- Verbal memory

Dopaminergic restoration has ameliorating, deleterious, and in some cases no effects on aspects of mild cognitive impairment that emerge during neuropsychological testing in the early stages of Parkinson's disease.

## Neurotrasmitters projection loss in PD



Noradrenergic dysfunction (locus coeruleus) in PD probably underlies the attentional set shifting deficit, which forms part of the dysexecutive syndrome.


Weintraub et al. *Neurology* 2010;75:448-455. Kehagia et al. *Brain* 2014;137:1986-1997.

Some frontal cholinergic deficit (cortico-striato-thalamic loop/nigrostriatal system) also compromises early Parkinson's disease cognition.


Bohnen et al. *Archives of Neurology* 2003;60:1745-1748. Meyer et al. *Arch Gen Psychiatry* 2009;66:866-877.

#### The cholinergic system and Parkinson disease

Nicolaas I. Bohnen a,b,c,\*, Roger L. Albin b,c,1



 PET imaging in patients with mild AD, PDD, and PD without dementia show greater and more extensive reductions in cortical AChE levels in PDD compared to AD of similar dementia severity [Bohnen NI 2003].




- Cortical cholinergic denervation affects esecutive processes [Bedard MA, 1999] and include symptoms such as visual allucination, depression and/or apathy and impaired activities of daily living [BohnenN 2007,2009].
- Subcortical cholinergic denervation, may relate to hyposmia, the presence of dopamine non-responsive gait and balance impairments, including falls, in PD [Stein JF et al 2009].


Department of Radiology, University of Michigan, Ann Arbor, MI, USA


Department of Neurology, University of Michigan, Ann Arbor, MI, USA

c VA Ann Arbor Healthcare System, Ann Arbor, MI, USA

# The pattern of Cognitive Impairment in PD is heterogeneous







### Spectrum of cognitive impairment in PD

**Normal Cognition** 

PD-MCI 30% (20-55%)

PDD 50% at 15ys

- Cognitive impairment
- Normal general cognitive functioning
- Normal functioning in activities of daily living
- Severe cognitive impairment
- Impairing daily function

### Dementia in Parkinson's Disease (PDD)

- The **point prevalence** is **30%** and the incidence rate is increased 4 to 6 time compared to age-matched controls (*Emre et al., 2007*).
- The **cumulative prevalence** is reported to be up to 83% after 20 years of follow up (Williams-Gray et al. 2013; Hely et al 2008; Perez et al., 2012).
- The main risk variables include higher age, lower education, longer disease duration, depression, hallucination, MCI at baseline, rigidity, gait disturbance and postural instability.









"This is a second opinion. At first, I thought you had something else."

.....only 25% of PD pts with dementia are recognised by clinicians in routine care

### Parkinson with mild cognitive impairment (PD-MCI)

Mild cognitive changes even in newly diagnosed, untreated PD, are associated with increasing age, disease duration, and disease severity (Biundo et al., 2013, Aarsland et al., 2011; Troster et al., 2011; Williams-Gray et al., 2007).


PD patients have an increased risk of developing cognitive impairment, and those with MCI may progress to dementia more frequently and more rapidly than those without cognitive impairment (CI) (Pedersen et al 2013; Barone et al., 2011; Janvin et al., 2006; Williams-Gray et al., 2009).

# Cognition in Untreated, Early PD: PPMI Study

Cognitive Domain	Variable	Mean (SD) or N (%)
Global	MOCA score (N=423)	27.1 (2.3)
	30 - 26	330 (78%)
	21 - 25	89 (21%)
	<2.1	4 (1%)
Visuospatial	Benton Judgment of Line Orientation Score	12.8 (2.1)
	(N=422)	
	Mild Impairment <sup>a</sup>	30 (7%)
	Moderate Impairment <sup>b</sup>	14 (3%)
	Severe Impairment <sup>c</sup>	2 (0%)
Memory	HVLT Immediate Recall (N=422)	24.4 (5.0)
	Mild Impairment	131 (31%)
	Moderate Impairment	73 (17%)
	Severe Impairment	29 (7%)
	HVLT Delayed Recall (N=422)	8.4 (2.5)
	Mild Impairment	139 (33%)
	Moderate Impairment	70 (17%)
	Severe Impairment	26 (6%)
	HVLT Retention (N=422)	0.9 (0.2)
	Mild Impairment	89 (21%)
	Moderate Impairment	47 (11%)
	Severe Impairment	21 (5%)
	HVLT Discrimination Recognition (N=421)	9.6 (2.6)
	Mild Impairment	102 (24%)
	Moderate Impairment	38 (9%)
	Severe Impairment	13 (3%)
Executive abilities-	Letter Number Sequencing Raw Score	10.6 (2.7)
Working memory	(N=422)	e
	Mild Impairment	28 (7%)
	Moderate Impairment	19 (4%)
	Severe Impairment	4 (1%)
	Semantic Fluency Total Score (N=422)	48.7 (11.6)
	Mild Impairment	61 (14%)
	Moderate Impairment	22 (5%)
	Severe Impairment	9 (2%)
Processing speed-	Symbol Digit Modalities Score (N=422)	41.2 (9.7)
Attention	Mild Impairment	110 (26%)
	Moderate Impairment	60 (14%)
	Severe Impairment	27 (6%)

# Frequent Progression From MCI to Dementia Over 3-5 Years

Long-term outcomes for incident MCI in established PD



Pigott et al. Neurology (in press).

Early MCI detection may ameliorate accuracy of Dementia and enhance the pharmacological and rehabilitation treatment



To implement rehabilitative interventions can ultimately have great effect on patients quality of life, cognitive symptom relief and promotion of functional independence

#### FEATURED ARTICLE



### Diagnostic Criteria for Mild Cognitive Impairment in Parkinson's Disease: *Movement* Disorder Society Task Force Guidelines

Irene Litvan, MD, <sup>1\*</sup> Jennifer G. Goldman, MD, MS, <sup>2</sup> Alexander I. Tröster, PhD, <sup>3</sup> Ben A. Schmand, PhD, <sup>4</sup> Daniel Weintraub, MD, <sup>5</sup> Ronald C. Petersen, MD, PhD, <sup>6</sup> Brit Mollenhauer, MD, <sup>7</sup> Charles H. Adler, MD, PhD, <sup>8</sup> Karen Marder, MD, <sup>9</sup> Caroline H. Williams-Gray, MRCP, PhD, <sup>10</sup> Dag Aarsland, MD, PhD, <sup>11</sup> Jaime Kulisevsky, MD, PhD, <sup>12</sup> Maria C. Rodriguez-Oroz, MD, PhD, <sup>13</sup> David J. Burn, MD, FRCP, <sup>14</sup> Roger A. Barker, BSc, MBBS, MRCP, PhD, <sup>10</sup> and Murat Emre, MD<sup>15</sup>

#### III. Specific guidelines for PD-MCI level I and level II categories

A Level I (abbreviated assessment)

- Impairment on a scale of global cognitive abilities validated for use in PD<sup>a</sup> or
- Impairment on at least two tests, when a limited battery of neuropsychological tests is performed (i.e., the battery includes less than two tests within each of the five cognitive domains, or less than five cognitive domains are assessed)
- B Level II comprehensive assessment)
- Neuropsychological testing that includes two tests within each of the five cognitive domains (i.e., attention and working memory, executive, language, memory, and visuospatial)<sup>b</sup>
- Impairment on at least two neuropsychological tests, represented by either two impaired tests in one cognitive domain or one impaired test in two different cognitive domains
- Impairment on neuropsychological tests may be demonstrated by:
  - o Performance approximately 1 to 2 SDs below appropriate norms or
  - o Significant decline demonstrated on serial cognitive testing or
  - o Significant decline from estimated premorbid levels

Impairment on a scale of globale cognitive ability or in at least two tests

- Two test for each of the 5 cognitive domain: attention, executive, language, memory and visuo-spatial
- Impairment (> 1, 1.5, 2 SD below the normative mean) on at least two NPSI tests

Journal of Parkinson's Disease 4 (2014) 131–137 DOI 10.3233/JPD-130304 IOS Press

#### Review

### Parkinson's Disease Mild Cognitive Impairment: Application and Validation of the Criteria



Fig. 1. Participating countries in the MDS PD-MCI Validation Study Group are marked black.

To validate the MDS PD-MCI criteria by pooling and analyzing cross-sectional and longitudinal neuropsychological databases comprising  $\geq 5,500$  PD patients and  $\geq 1,700$  controls.

### Current issues about PD-MCI



Neuropsychological issues. No specific global cognitive scale (MMSE vs MoCA) or neuropsychological test battery to detect cognitive impairment in PD or cognitive decline over time (Biundo et al 2013; Marras et al 2010; Lessig et al 2012; Hu et al 2014)



Statistical issues. A threshold values (-1 or -1.5 or -2 SD) is a rather crude approach assuming each test contributes in an equivalent manner to identify the cognitive state of the individual examined (Biundo et al.2013)


- Neuroimaging issues. Cortical changes associated with cognitive decline in PD are not fully explored and required investigations (Biundo et al 2014; Rektorova et al 2014; Weintraub 2011, Meltzer 2012)
- Clinical issues. No consensus about PD-MCI profile that can predict dementia (Biundo 2014; Williams Gray 2013; Goldamm-Litvan 2011)



### Heterogeneity of cognitive impairment in PD

Different neuropsychological profiles

Different clinical mainfestations




Lancet Neurology, 2010


Diverse underlying neurochemistry

Different underlying neurosubstrates

There is neuropsychological overlap because PDD have acetylcholine-based visuo-spatial and memory deficits as well as dopamine-dependent executive deficits, noradrenergic-dependent executive deficits, and some degree of frontal cholinergic deficit might also contribute to cognitive impairment early in the disease course.

# ..where do we start assessing cognitive status?





### PD-MCI detection

#### FEATURED ARTICLE



## Diagnostic Criteria for Mild Cognitive Impairment in Parkinson's Disease: *Movement* Disorder Society Task Force Guidelines

Irene Litvan, MD, 1\* Jennifer G. Goldman, MD, MS, 2 Alexander I. Tröster, PhD, 3 Ben A. Schmand, PhD, 4 Daniel Weintraub, MD, 5 Ronald C. Petersen, MD, PhD, 6 Brit Mollenhauer, MD, 7 Charles H. Adler, MD, PhD, 8 Karen Marder, MD, 9 Caroline H. Williams-Gray, MRCP, PhD, 10 Dag Aarsland, MD, PhD, 11 Jaime Kulisevsky, MD, PhD, 12 Maria C. Rodriguez-Oroz, MD, PhD, 13 David J. Burn, MD, FRCP, 14 Roger A. Barker, BSc, MBBS, MRCP, PhD, 10 and Murat Emre, MD, 15

Subject complaints of cognitive deficits

Normal functioning on activity of daily living

Level I
Impairment on a scale of
globale cognitive ability

# Eliciting cognitive concerns and assessing function related to cognition

- Ask patient AND companion Global questions: "do you have concerns about your memory or thinking?" or "does it interfere with your ability to carry out your activities?"
- Cognitive complaint interview
- Functional rating scales:

PD-Cognitive functional rating scale Disability assessment for Dementia Pill Questionnaire

Neuropsychological assessment

### Cognitive complaint interview

	Questions concerning the last 6 months	Response
1	Have you observed a memory change during the last 6 months?	Yes/no
2	During the last 6 months, do you consider that your memory has been worse than the memory of your peers?	Yes/no
3	Do you record less recent events or have you heard your family say 'I have already said so to you'?	Yes/no
4	Do you often forget appointments?	Yes/no
5	Do you often forget where things are left?	Yes/no
6	Do you have more difficulty finding your way in your neighborhood? Have you ever not recognized a route that your family thinks you have already gone?	Yes/no
7	Have you ever forgotten a whole event, even when the family gives you clues, details or pictures of the event?	Yes/no
8	Have you ever encountered difficulty finding particular words (except person names)?	Yes/no
9	Have you reduced your activities (social or leisure's activities, association, papers and invoices) or asked your family to help you because you are afraid you may make a mistake?	Yes/no
10	Have you ever observed mood changes in term of apathy, blunted affect, inertia, loss of volition or interest for activities or persons?	Yes/no

10 items (6 on memory)

>3 = complaint

Several studies in the elderly have suggested that cognitive complaints (when recorded using standardized items) may help to predict dementia (Thomas Anterion C., 2003; Miranda B et al., 2008)

# Eliciting cognitive concerns and assessing function related to cognition

- Ask patient AND companion Global questions: "do you have concerns about your memory or thinking?" or "does it interfere with your ability to carry out your activities?"
- Cognitive complaint interview
- Functional rating scales:

PD-Cognitive functional rating scale

Pennsylvania Daily Activities Questionnaire

Pill Questionnaire

Neuropsychological assessment

# Parkinson's Disease Cognitive Functional Rating Scale (PD-CFRS)

1 Ha difficoltà a maneggiare denaro?Per esempio: controllare il resto, calcolare quanto le serve per fare degli acquisti ecc.	0	1	2	8
2 Riscontra delle difficoltà nella gestione dell'amministrazione di casa?	0	1	2	8
3 Ha delle difficoltà nel pianificare le sue vacanze o degli appuntamenti con amici/familiari?	0	1	2	8
4 Riscontra delle difficoltà nel gestire la posta in arrivo, o ad organizzare le sue bollette e gli appuntamenti con il medico?	0	1	2	8
5 Ha delle difficoltà nel ricordare quando assumere i farmaci e in quale dose?	0	1	2	8
6 Riscontra delle difficoltà nel pianificare le attività quotidiane nell'arco della sua giornata?	0	1	2	8
7 Trova difficile ultimamente capire come utilizzare gli apparecchi elettrodomestici?	0	1	2	8
8 Riscontra delle difficoltà a pianificare il suo percorso utilizzando mezzi pubblici?	0	1	2	8
9 Trova difficoltà nel gestire delle situazioni o problemi inaspettati?	0	1	2	8
10 Trova difficoltà qualche volta a farsi capire?	0	1	2	8
11 Ha delle difficoltà a comprendere quello che legge (libri, riviste, giornali)?	0	1	2	8
12 Trova difficoltà nel capire come funziona un telefono cellulare?	0	1	2	8

Kulisevsky J. et al. 2013

PD-CFRS cut-off score of > 3 for detecting functional impairment in PD-MCI PD-CFRS cut-off score of > 6 for detecting functional impairment in PDD

### Pennsylvania Daily Activities Questionnaire (PDAQ)

(Weintraub, D; Brennan et al. 2015)

Please check or fill in the following that best describes you.

O None (4)	O A Little (3)	O Somewhat (2)	O A Lot (1)	O Cannot D	0 (0)
2. How much [ clock)?	DIFFICULTY do	you currently have ke	eping track of tim	e (e.g. using a	
O None (4)	O A Little (3)	O Somewhat (2)	O A Lot (1)	O Cannot D	0 (0)
	ting the refriger	CULTY do you currer rator fixed)?	illy flave flaffulli	ig an umamilia	ii problem (e.g.
O No	one (4) O A	Little (3) O Sor	mewhat (2)	O A Lot (1)	O Cannot Do (0)

# Eliciting cognitive concerns and assessing function related to cognition

- Ask patient AND companion Global questions: "do you have concerns about your memory or thinking?" or "does it interfere with your ability to carry out your activities?"
- Cognitive complaint interview
- Functional rating scale
   PD-Cognitive functional rating scale
   Pennsylvania Daily Activities Questionnaire
   Pill Questionnaire
- Neuropsychological assessment

# Eliciting cognitive concerns and assessing function related to cognition

- Ask patient AND companion Global questions: "do you have concerns about your memory or thinking?" or "does it interfere with your ability to carry out your activities?"
- Cognitive complaint interview
- Functional rating scale
   PD-Cognitive functional rating scale
   Pennsylvania Daily Activities Questionnaire
   Pill Questionnaire
- Neuropsychological assessment

### Tools

Global cognitive rating scale

- Neurospychological testing
- > Clinical interview
- > Detailed cognitive testing
- > Feedback session

½ day



## Validated cognitive scales

#### Non-specific for PD


- Mattis Dementia Rating Scale (MDRS)
  - measures frontal-subcortical deficits
- Mini-Mental State Examination (MMSE)most commonly used for dementia but low sensitivity to detect MCI
- Cambridge Cognitive Assessment (CAMCOG) accurate for diagnosis of PDD
- Frontal Assessment Battery (FAB)
   Non-compatible with pattern of CI
   predominant in PD

#### **Specific for PD**

- The MoCA brief screening test covering the whole spectrum of CI in PD patients
- Parkinson's Disease Cognitive Rating Scale (PD-CRS)designed to capture the whole spectrum of CI in PD patients
- Parkinson Neuropsychometric Dementia Assessment (PANDA) designed to screen for CI in PD patients
- Scales for Outcomes of Parkinson's Disease-Cognition (SCOPA-COG) mainly assesses frontal-subcortical function

# Montreal Cognitive Assessment (MoCA)

- MoCA (maximum score 30)
- 7 subscores:
- visuospatial/executive (5 points);
- naming (3 points);
- memory (5 points for delayed recall);
- attention (6 points);
- language (3 points);
- abstraction (2 points);
- orientation (6 points).
- One point is added if the subject has 12 years of education.



## Mini-Mental State Exam (MMSE)

- MMSE (maximum score 30)
- Orientation
- Registration
- Attention and calculation
- 3 words recall
- Language: denomination, repetition, comprehension, writing.
- Visuo-spatial skills


### The Mini-Mental State Exam


Patient	-	Examiner	Date
Maximum	Score		
		Orientation	
5	( )	What is the (year) (season) (date) (day) (month)?	
5	( )	Where are we (state) (country) (town) (hospital) (floor)?	
		Registration	
3	( )	Name 3 objects: 1 second to say each. Then ask the patient all 3 after you have said them. Give 1 point for each confine Then repeat them until he/she learns all 3. Count trials	rrect answer.
		Attention and Calculation	
5	( )	Serial 7's. 1 point for each correct answer. Stop after 5 an Alternatively spell "world" backward.	swers.
		Recall	
3	( )	Ask for the 3 objects repeated above. Give 1 point for each	correct answer.
		Language	
2	( )	Name a pencil and watch.	
1	( )	Repeat the following "No ifs, ands, or buts"	
3	( )	Follow a 3-stage command:  "Take a paper in your hand, fold it in half, and put it on	the floor."
1	( )	Read and obey the following: CLOSE YOUR EYES	
1	( )	Write a sentence.	
1	( )	Copy the design shown.	
		Total Score	
		ASSESS level of consciousness along a continuum	<u></u>
		Alert Drowsy Stupor	Coma

## Attention and Working Memory

- Spatial span
- Digit Ordering Test
- Trail Making Test








### Sustained attention


Digit (	Digit Ordering-B					
Item	Span length	Trial 1	1/0	Trial 2	1/0	Score (0-2)
1.	3	483		727		
		(348)		(277)		
2.	4	9584		6165		
		(4589)		(1 5 6 6)		
3.	5	37642		62963		
		(23467)		(2 3 6 6 9)		
4.	6	372816		414836		
		(123678)		(1 3 4 4 6 8)		
5.	7	6320715		8541752		
		(0123567)		(1245578)		
6.	8	48729361		15210764		
		(12346789)		(01124567)		
Notes:		•		Test score (max. 12):		
				Percentile of test score:		
				Maximal span:		


Cognitive flexibility



### **Executive Functions**


- Phonemic Fluency (words beginning with a given letter)
- Stroop Test (response inhibition: say the color of the ink)





## Language

- Denomination Test
- Category Fluency Task (words pertaining to a semantic category)








MARCHE D'AUTO	FRUTTI	ANIMALI
FIAT I	PERA	CANE
LAN CIAZ	PERDURARE	GHEP 3
4 SERATIS	PURE	LEOP 3
ERBACI 4	PICCH (I ETTARE	ELEFANTE
-EKBRIG	PICCE (I E WAKE	Disco
	PAUDINEGGIARE	PW70 0
		PANTILO
		-
2.0		
		-
4. /.	T-4:	Tet
t.: 4	Tot.:	Tot.: 4


## Visuo-spatial Functions

- Letters Recognition (VOSP)
- Rey-Osterrieth ComplexFigure Test (copy)
- Clock Drawing test copy











## Memory

- Cued Recall Test (frontal or posterior deficits?)
- Prose Memory Test
- Rey-Osterrieth Complex Figure test (recall)





APPRENDIMENTO DI COPPIE	TVI	PAROLE	ė
APPRENDIMENTO DI CUPPUS	A/A.	PARAMETER.	

PRESENTAZIONE 1	CUE	KISPOSIE	FUNIEGOEG
FRUTTA - UVA	BACIO		
SCUSA - FEDE	SCUSA		
MESE - ANNO	NORD		
PONTE - VINO	ARCO		
ALTO - BASSO	ALTO		
BACIO - MURO	PONTE		
NORD - SUD	FRUTTA		
PESCE - MARE	LOTTA '		
ARCO - NOME	PESCE		
LOTTA - DITO	MESE		WANT I
			TOT 1
PRESENTAZIONE 2			
FRUTTA - UVA	SCUSA		
BACIO - MURO	LOTTA		
SCUSA - FEDE	ALTO		
NORD - SUD	FRUTTA		
ARCO - NOME	PESCE		
PESCE - MARE	ARCO		
ALTO - BASSO	BACIO		
LOTTA - DITO	PONTE		1 1
MESE - ANNO	MESE		
PONTE -VINO	NORD		
			TOT 2
PRESENTAZIONE 3			
ARCO - NOME	PESCE		
MESE - ANNO	FRUTTA		
NORD - SUD	NORD		
SCUSA - FEDE	SCUSA		
LOTTA - DITO	PONTE		
ALTO - BASSO	LOTTA		-
PESCE - MARE	MESE		1
BACIO - MURO	BACIO		1
FRUTTA - UVA	ARCO		-
PONTE - VINO	ALTO		TOT 3
		TAZIONE 1+2+3	A Company of the Comp


# PDD detection

### Diagnostic Procedures for Parkinson's Disease Dementia: Recommendations from the Movement Disorder Society Task Force

TABLE 2. Diagnostic rating sheet for probable PD-D, recommended by the Movement Disorder Task Force

		YES	NO
1.	Parkinson's disease		
2.	Parkinson's disease developed before dementia		
3.	MMSE <26		
4.	Dementia has Impact on ADLs		
5.	Impaired cognition (For Yes, at least of 2 of 4 tests		
	below are abnormal)		
	Mark which Tests are abnormal		
	☐ Months reversed or Sevens backwards		
	Lexical fluency or clock drawing		
	☐ MMSE pentagons		
	3-word recall		
6.	Absence of Major Depression		
7.	Absence of delirium		
8.	Absence of other abnormalities that obscure diagnosis		
	Probable PD-D (items 1-8 must all be YES)		


Movement Disorders Vol. 22, No. 16, 2007, pp. 2314-2324 © 2007 Movement Disorder Society




MONTREAL COGNITIVE ASSESSMENT (MOCA) - ITALIA -	NOME: Scolarità: Sesso:	Data di nascita: DATA:	
VISUOSPAZIALE / ESECUTIVO	Copi Il cubo	Disegni un orologio (undici e dieci	) PUNTI
E A S Fine B 2 C C		(3.7 s)	
1.1	[]	[+] [4]- [-] Contorno Numeri Lancette	1/5
DENOMINAZIONE		H	3_13
MEMORIA Leggere la lista di parole: il soggetto deve ripelerle. Fare le prime 2 prove di seguito e il "Richiamo" dopo 5 min. 2° prova 2° prova	Velluto	Chiesa Margherita Rosso	0 punti
ATTENZIONE  Leggere la serie di cifre (una cifra / sec.)  Il soggetto deve rip Il soggetto deve rip		[-] 21854	1_12
Leggere la serie di lettere. Il soggetto deve dare un colpetto con la mano s [ ] FBACMNAAG		gnilettera "A". 0 puntise ≥ 2 errori . H DEAAAGAMOFAAB	0/1
Sottrazione di 7 partendo da 100 per 5 volte [ ] 93 [ ] 86 4 o 5 sottrazioni corrette: 3 pt,	[ ] <b>7</b> 9	9 [ ] 72 [ ] 65 2 pt, 1 corretta: 1 pt, 0 corretta: 0 pt	1/3
LINGUAGGIO Ripeta: So solo che oggi dobbiamo aiutare Giovanni. Il gatto si nascondeva sempre sotto il divano	guando c'er	□ [-] ano cani nella stanza.	<u>O</u> 12
Fluenza / In 1 minuto, nomini il maggior numero possibile di parole che i			0/1
ASTRAZIONE Similitudini tra per es. banana / arancio = frutti;	[-] treno	/ bicicletta [-] orologio / righello	012
RICHIAMO DIFFERITO  Deve ricordarsi le parole SENZA AIUTO  Faccia [ ]  [ ]  AIUTO	[]	Margherita Rosso Punti solo per ripetizione SENZA AIUTO	_/5
Opzionale Scelta multipia + +  ORIENTAMENTO [-] Data  -] Mese [-] Anno	[+] Giorno	H Luogo H Città	416
Z. Nasreddine. Traduzione a cura di A. Pirani, C. Tulipani, M. Neri.	Normale: ≥ 26 / 30	TOTALE  Aggiungere 1 punto se ≤ 12 anni di i	11/30


# Trail Making test

**TMTA** 





**TMTB** 







# Clock drawing test








# Rey Figure immediate and delayed copy



Direct copy



Delayed copy



### Case C.D.

- Men
- Age: 49 years
- Edu: 13 years
- Left/righ handed
- Family history: negative for neurological disease
- Personal history: unremarkeble
- Concomitant pathologies: none
- Disease onset: 2004 (Sx)

# Neuropsychological assessments

2009

- Executive deficits
- Attention deficits
- Working memory deficits
- Visuo-perceptive deficits
- Language normal
- Temporo-spatial oriented

2011

- Previuos cognition abilities marketly worsened
- Language deficits (anomia)
- Apraxia with closing-in


2010


- Temporal disoriented
- Physical and Verbal disinhibition
- Executive deficits + perseveration
- Marked Attention deficits
- Working memory deficits
- Visuo-perceptive deficits
- Amnesic deficits
- ICD (Hypersexuality)
- Depressed (BDI 18)

## Neuropsychological assessments

2009 MOCA 18


2010 MOCA 19






# Visuo-spatial skills impaired


**REY'S FIGURE** 





**IMMEDIATE COPY** 





### **DELAYED RECALL**













MMSE 20.2


MMSE 8.2

MMSE 6.2









### FLUENZE SEMANTICHE

ANCIA TASERATI 3 FERRAL I EUGTOT S CRYSIER 6 DOODRE 7	FRUTTI NOCADO I UNA 2 VANGO 3 SUSAFO ( TIGLE 5 NOC: 6 MADARINO 3 ARANCO 8	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	HERARDO S
ANCIA TASERATI 3 FERBAL I EUGTOT 5 CRYSTER 6 DOODRE 7 DRSCHE 8	14NGO 3 15X42 4 110E 5 NOC: 6	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	TGRE LEFANTE 3 DELFINO ( HÈPARDO S DRATA ( DEPPIA
TASERATI 3 FERRAL ( EUCTOT S CRYSTER 6 DOODLE 7 DRISCHE 8	YANGO 3 SCHE 4 MGC: 5 MOC: 6 MANDARINO X	4 4 0 8	LEFANTE 3 DELFINO ( HÉPARDO S DRATA S DOGLIOLA ( SEPPIA
FERRAL (1) EUCTOT S CRYSTER 6 DOODLE 7 DRISCHE 8	MOC: 6	4 G S	PRATA COGLIOLA
EUCTOTS CRYSCER 6 DOODLE 7 DRSCHIZ 8	MOCI 6 MANDARINO 2	\( \frac{\alpha}{\sigma} \)	HÎRARDO S PRATA S OGLIOLA S SEPPIA
CRYSTER 6 DOODBE 7 DRSCHE 8	MOCI 6 MANDARINO 2	8 9	DRATA ( DOG-LIOVA S SEPPIA
DOODLE 7 O	MANDARINO 2	8	OG-LIOLA .
DRSCH2 8	ARANCIO 8	S	3011194
^	ARANCIO 8		3011194
OPE ( 9			ANE
		1 0	11110
		1 5	ATTO
		] [	
		1	
		1 🗆	
		1 -	
		1	
		1 -	
		1 -	
		1 -	
		- H	
, , , , , ,		- ⊢	
		<b>↓</b>	
		1 -	
		J L	

7=	L	Р
	deone 1	PALERTO
was te		PULIRE
		PAPAVERO
		PAPAVERO
		-
		(PUATO)
		PRODICIAESIL PICCO S
		PKC0 5
		1
t: 0	Tot.: A	Tot.: S
nteggio grezzo:	6	
Meggio corretto:	* 2	
rteggio equivalente:	0	

Deta:	Cognome:	Nome:			
<u>Notacioni.</u> "Ona le chiecerò di dimi 1ulli i nomi di ("marche d'auto) che le vengono in mente. Ha un minute di tempe.					
MARCHE D'AUT	A POLICE	1. 1.00			
Punteggio grezzo: Punteggio cometto:	-	$\exists$			
unteggio equivalent	te:				
Osseovacioni;					



# Take home messagges

- Testing Conditions
- ✓ ON therapy (verify at the beginning and at the end of testing)
- ✓ Well rested
- Assess mood and anxiety
- Rule out other medical conditions that may affect cognition:
- ✓ Active infection, thyroid, hepatic or renal disorders

# Take home messagges

- Ask about cognitive concerns and functions related to cognition (patient + collateral historian)
- Use a global test to screen for cognitive impairment
- If diagnosis is uncertain, refer for neuropsychological testing
- Repeat cognitive assessment every 12-18 months for PD-MCI.

# Conclusion

- Cognitive impairment is an important part of PD, can be present early in the course of the disease and frequently leads to dementia.
- Fronto-striatal alterations are characteristic of PD physiopathology
- PD-MCI is an heterogeneous condition with attentive/ executive tasks most frequently altered.
- Identifications of PD-MCI is important to develop therapeutic strategies that may slow down cognitive decline.